Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | ADH5 | P11766 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113384 | 0.77 | RPA1 (0.48) | ATMADH5MEN1ALDH1A1KMT2A | |
| SCHEMBL15422384 | 0.77 | MAPT (0.45) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL1236194 | 0.73 | ATM (0.44) | ATMPBRM1ADH5MEN1ALDH1A1 | |
| SCHEMBL957255 | 0.73 | CDC7 (0.49) | ATMADH5MEN1ALDH1A1KMT2A | |
| SCHEMBL29400863 | 0.72 | MAPT (0.50) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL197157 | 0.68 | SNCA (0.50) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL7865703 | 0.67 | HDAC1 (0.52) | MEN1ALDH1A1KMT2AL3MBTL1GAA | |
| SCHEMBL5453288 | 0.66 | SNCA (0.48) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL5889177 | 0.66 | SNCA (0.48) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL5889194 | 0.66 | SNCA (0.48) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-2178876-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | AstraZeneca AB (SE) | 2010-04-28 | — | — | EP | disclosed |
| CN-101687871-A | Spiro condensed barbituric acid derivatives for use as antibacterial | ASTRAZENECA UK LTD | 2010-03-31 | — | — | CN | disclosed |
| WO-2009010801-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
| US-20050267054-A1 | Antibacterial compounds with improved pharmacokinetic profiles | CLARK RICHARD F | 2005-12-01 | — | — | US | disclosed |
| EP-1501845-A1 | ANTIBACTERIAL COMPOUNDS WITH IMPROVED PHARMACOKINETIC PROFILES | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040033970-A1 | Antibacterial compounds with improved pharmacokinetic profiles | ABBOTT LABORATORIES | 2004-02-19 | — | — | US | disclosed |
| WO-2003093288-A1 | ANTIBACTERIAL COMPOUNDS WITH IMPROVED PHARMACOKINETIC PROFILES | ABBOTT LABORATORIES (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030207820-A1 | Antibacterial compounds with improved pharmacokinetic profiles | ABBOTT LABORATORIES | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | ATM 3314/4885PBRM1 1766/4885ADH5 1237/4885 |
| US-20050267054-A1 | Antibacterial compounds with improved pharmacokinetic profiles | ABCB11, SLC10A2, SI | ATM 4504/4885PBRM1 4328/4885ADH5 1663/4885 |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | ATM 1904/4885PBRM1 825/4885ADH5 531/4885 |
| US-20030207820-A1 | Antibacterial compounds with improved pharmacokinetic profiles | UGT1A1, ABCB11, SLC10A1 | ATM 4689/4885PBRM1 3428/4885ADH5 1941/4885 |
| US-20040033970-A1 | Antibacterial compounds with improved pharmacokinetic profiles | UGT1A1, ABCB11, SLC10A1 | ATM 4689/4885PBRM1 3428/4885ADH5 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.